RxDoctor Payments DataLook up a doctor →

Isaac Levy, MD

Hematology-Oncology · Pembroke Pines, FLNPI 1871577221

Payments from drug & device makers

$3,332,698in general payments, 2019–2025

Across 1,471 payments — averaging $2265.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.9M
  • Eli Lilly$199K
  • Karyopharm Therapeutics Inc.$36K
  • Sanofi$35K
  • Incyte Corporation$30K
  • Amgen$24K
  • plus $66K from 54 others
$17,303in research payments, 2019–2025

Across 7 payments — averaging $2471.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$14K
  • Eli Lilly$3K
  • Spectrum Pharmaceuticals Inc.$385

What the payments were for

  • Consulting fees$23,27743%
  • Speaking & faculty fees$1,0002%
  • Travel & lodging$1,6513%
  • Food & beverage$27,04249%
  • Education$1,4963%
  • Other$2991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis118$2,943,405
Eli Lilly43$198,809
Karyopharm Therapeutics Inc.8$35,501
Sanofi52$35,166
Incyte Corporation62$29,667
Amgen27$23,891
Sanofi US Services Inc.22$16,841
AstraZeneca(2 entities)158$14,904
Pfizer128$11,955
Merck73$3,725
E.r. Squibb & Sons, L.L.C.81$3,319
Johnson & Johnson(2 entities)118$2,452
Rigel Pharmaceuticals, Inc.24$972
Astellas Pharma US Inc36$959
GSK45$930
Bristol Myers Squibb50$929
Beigene USA, Inc.13$697
Eisai Inc.34$658
Seagen Inc.25$623
AbbVie25$572
Lilly USA, LLC25$452
Array Biopharma Inc32$420
Takeda Pharmaceuticals U.S.A., Inc.17$405
Exelixis Inc.22$329
Genentech USA, Inc.16$315
Myriad Genetic Laboratories, Inc.10$305
Daiichi Sankyo Inc.12$285
Sobi, Inc9$250
Epizyme, Inc.9$244
Bayer12$238
Adaptive Biotechnologies Corporation11$237
Taiho Oncology, Inc.11$216
Stemline Therapeutics Inc.10$200
Regeneron Healthcare Solutions, Inc.9$197
Gilead(2 entities)8$183
Medtronic(2 entities)3$159
Pharmaessentia USA Corporation8$153
Dova Pharmaceuticals7$130
Mirati Therapeutics, Inc.6$120
Janssen Scientific Affairs, LLC3$103
Sumitomo Pharma America, Inc.4$102
Ipsen Biopharmaceuticals, Inc5$92
Deciphera Pharmaceuticals Inc.5$90
Tempus AI, Inc4$85
Pharmacyclics LLC, An Abbvie Company4$83
Myovant Sciences Inc.4$79
Foundation Medicine, Inc.4$74
EMD Serono, Inc.4$72
Geron Corporation3$70
Teva Pharmaceuticals USA, Inc.4$68
Caris MPI, Inc.3$67
Servier Pharmaceuticals LLC3$65
Fennec Pharmaceuticals, Inc.3$63
Tersera Therapeutics LLC3$59
Verastem, Inc.3$57
Amneal Pharmaceuticals LLC3$54
Partner Therapeutics, Inc.3$49
Iovance Biotherapeutics, Inc.2$46
Tesaro, Inc.2$46
Legend Biotech USA Inc.1$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology-oncology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$375,754
Medicare patients
118
Services billed
18,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide64$769,203
Darzalex FasproDaratumumab-Hyaluronidase-Fihj40$711,396
ImbruvicaIbrutinib37$574,380
BrukinsaZanubrutinib36$547,817
ErleadaApalutamide18$281,555
TasignaNilotinib Hcl12$226,062
TagrissoOsimertinib Mesylate12$209,515
Abiraterone Acetate21$118,418
DarzalexDaratumumab24$114,998
PromactaEltrombopag Olamine12$86,423
PerjetaPertuzumab12$76,755
OrgovyxRelugolix19$59,651
XgevaDenosumab17$54,974
Imatinib Mesylate28$20,983
EliquisApixaban25$20,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$83$574,38037 claims
Beigene USA, Inc.Brukinsa$697$547,81736 claims
Johnson & JohnsonErleada, Darzalex$2,452$396,55242 claims
NovartisTasigna, Promacta$2,943,405$312,48524 claims
AstraZenecaTagrisso$14,904$209,51512 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$103$118,41821 claims
Sumitomo Pharma America, Inc.Orgovyx$102$59,65119 claims
AmgenXgeva$23,891$54,97417 claims
PfizerEliquis$11,955$20,20825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other hematology-oncology in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →